I stay on the cutting edge of industry and enjoy finding out about new companies that major outlets and funds haven't heard of (yet). Most of the time you can find me deep in the corporate filings, focusing on fundamentals that could be behind the next big move in certain stock.
GT Biopharma Adds University of Wisconsin–Madison Carbone Cancer Center as Second Site in Ongoing Phase 1/2 Clinical Trial of GTB-3550 TriKE™, a Novel NK Cell Therapeutic Cancer Treatment
BEVERLY HILLS, Calif., March 4, 2021 /PRNewswire/ — GT Biopharma, Inc. (NASDAQ:…